Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleRandomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
Author(s)Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ.
Journal, Volume, IssueMult Scler. 2010 Nov;16(11):1349-59.
Major outcome(s)The cannabis extract had some effect on overactive bladder symptoms.
IndicationMultiple sclerosisAbstract
MedicationCannabis

BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). Objective: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We undertook a 10-week, double-blind, randomized, placebo-controlled, parallel-group trial in 135 randomized subjects with MS and overactive bladder (OAB). RESULTS: The primary endpoint was the reduction in daily number of urinary incontinence episodes from baseline to end of treatment (8 weeks). Other endpoints included incidence of nocturia and urgency, overall bladder condition (OBC), daytime frequency, Incontinence Quality of Life (I-QOL), Patient's Global Impression of Change (PGIC) and volume voided. The primary endpoint showed little difference between Sativex and placebo. Four out of seven secondary endpoints were significantly in favour of Sativex: number of episodes of nocturia (adjusted mean difference -0.28, p = 0.010), OBC (-1.16, p = 0.001), number of voids/day (-0.85, p = 0.001) and PGIC (p = 0.005). Of the other endpoints, number of daytime voids was statistically significantly in favour of Sativex (-0.57, p = 0.044). The improvement in I-QOL was in favour of Sativex but did not reach statistical significance. CONCLUSIONS: Although the primary endpoint did not reach statistical significance, we conclude that Sativex did have some impact on the symptoms of overactive bladder in patients with MS, providing evidence of some improvement in symptoms associated with bladder dysfunction in these subjects.

Route(s)Sublingual
Dose(s)
Duration (days)70
Participants135 subjects with multiple sclerosis and overactive bladder
DesignControlled study
Type of publicationMedical journal
Address of author(s)National Hospital for Neurology and Neurosurgery, London, UK.
Full text

[Back to Overview]  [IACM Homepage]


up